Procarbazine hydrochloride is under clinical development by Alfasigma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Procarbazine hydrochloride’s likelihood of approval (LoA) and phase transition for Astrocytoma took place on 19 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Procarbazine hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Procarbazine hydrochloride overview

Procarbazine (Matulane / Natulan) is a benzamide derivative acts as anti-neoplastic agent. It is formulated as hard gelatin capsules for the oral route of administration. It is indicated for the treatment of Hodgkin's disease (multiple lymphadenoma); treatment of other malignant lymphomas including lymphosarcoma, reticulosarcoma and Brill-symmers disease. Natulan is dissimilar to other cytostatic agents and may be effective in cases resistant to other drugs and X-rays. Natulan is indicated for the treatment of hodgkin’s lymphoma in combination with chemotherapy.

It is under development for non Hodgkin's disease in China and for the treatment of oligodendrogliomas, oligoastrocytomas, and astrocytomas in the U.S.

Alfasigma overview

Alfasigma is a manufacturer and supplier of pharmaceutical products. The company offers prescription and over the counter drugs for the treatment of gastrointestinal disorders; drugs for diabetes and vascular diseases; nutraceuticals and medical foods. It also produces medicines to treat cardiology, orthopaedics, rheumatology, broncho-pneumology indications. Alfasigma is investigating drugs against gastroenterology, vascular disease and neuroscience disorders. The company operates a contract manufacturing office in Alanno, Pescara, Italy. It has operational presence in Belgium, China, Czech Republic, France, India, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovak Republic, Spain, Switzerland, Tunisia and the US. Alfasigma is headquartered in Bologna, Emilia-Romagna, Italy

Quick View Procarbazine hydrochloride LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Procarbazine hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.